Phosphate Binder Linked With Reduced Mortality
In a meta-analysis, hemodialysis patients using lanthanum carbonate to lower phosphorus levels had a 55% decreased risk of death compared with those taking other binders.
In a meta-analysis, hemodialysis patients using lanthanum carbonate to lower phosphorus levels had a 55% decreased risk of death compared with those taking other binders.
Sucroferric oxyhydroxide and sevelemer are similarly effective in lower phosphorus levels in dialysis patients, but the former is associated with less toxicity and lower pill burden.
The use of phosphate binders to manage hyperphosphatemia in maintenance hemodialysis patients might allow diets less restricted in protein and calories, according to a study.
Study results show that the phosphate binder was superior to placebo in raising hemoglobin levels in non-dialysis-dependent CKD patients with iron-deficiency anemia.
Phosphate binder use is associated with a 25% and 37% decreased risk of death from infection-related causes and all-causes, respectively, compared with non-users.
A randomized controlled pilot study demonstrated the feasibility and safety of performing a large clinical trial that is powered to establish whether phosphate lowering reduces fatal and nonfatal cardiovascular events.
Phase 2 randomized placebo-controlled trial demonstrated the safety and efficacy of sevelamer in lowering serum phosphorus levels in children and adolescents.
Of 7 phosphate binders, iron-based agents were optimal when efficacy and safety are considered.
The proportion of patients with serum phosphorus levels within target range rose from 22% to 65% within 6 months of starting ferric citrate treatment.
Use of sevelamer was associated with a 14% decreased risk of death compared with non-use.